anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a permeable spraying device for making drug tablets and a manufacturing process thereof. The permeable spraying device mainly includes a carrying platform, a spraying apparatus, a flattening device and a control apparatus. The carrying platform defines a powder dropping area and a flattened spraying area. A moving device combined with the carrying platform is capable of moving vertically. The spraying apparatus is mounted above the carrying platform. The spraying apparatus comprises a powder box, a colloid spraying apparatus, a driving device and a placement platform. The placement platform is disposed with a plurality of supplementary colloid carriers. The flattening device is disposed on the carrying platform and moves horizontally back and forth in the flattened spraying area. The control apparatus includes a storage unit and an execution control unit. The permeable spraying method of the present invention can be used to perform spraying at designated positions according to compositions of drug tablets, and a multi-layer drug body structure can be formed by deposition, stacking and bonding, which is not only faster in manufacturing, but also lower in cost.
In 2022, the FDA cleared a large dosage of repetitive transcranial magnetic stimulation for treatment-resistant depression (TRD), which requires 10 sessions per day of 1,800 pulses per session for a total of 18,000 pulses per day. The inter-session interval is 50 min, and it costs patients 9 hours for the intervention. The investigators assume that patients with moderate to severe depression may not need 10 sessions per day, patients may achieve response or remission with a less amount of dosage, which will save the cost of treatment. Hence, the investigators try to find the optimal treatment dosage for patients with moderate to severe depression.

After being informed about the study and potential risks. All patients giving written informed consent will undergo a screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner in a 1:1:1:1:1 ratio to each active rTMS group with different pulses (4×1800 pulses, 6×1800 pulses, 8×1800 pulses, 10×1800 pulses) and sham-control group. And then all participants will undergo a 5-day rTMS treatment followed by four- and eight weeks follow-up visits. Participants will keep a stable treatment regime during treatment and the four-week follow-up.
BACKGROUND: Self-care and preventive health strategies may trigger health inequities when individuals' cultural values and health beliefs are not fully understood and considered. In the case of cervical cancer (CC) screening programs immigrant women have shown lower attendance compared with native women, which increases the risk of late diagnosis and, consequently, a lower probability of survival. HPV self-sampling for CC screening has been recently added to the World Health Organization's (WHO) list of self-care interventions as a promising tool to reduce this disparity and improve screening coverage. In Catalonia, Spain, the introduction of HPV self-sampling as a part of the new population-based CC screening program, is a significant step. However, there is a lack of research addressing self-care and prevention among immigrant populations in this region. This study aims to fill this gap exploring self-care and prevention attitudes and practices among Moroccan and Pakistani women.
METHODS: We conducted focus groups and individual interviews with 36 Moroccan and 37 Pakistani women in Barcelona, Spain. The topic guide of the focus groups included case vignettes to stimulate the discussion and a semi-structured questionnaire was used for the interviews.
RESULTS: Our findings show that most Moroccan and Pakistani women do not prioritize self-care and prevention. They seek care for symptom treatment rather than disease prevention. In this sense, they reported not having the habit of doing regular check-ups and their self-care and prevention attitudes and practices seemed to be conditioned by cultural values. The implementation of an effective call and recall system could enhance the engagement of these populations with CC screening services.
CONCLUSION: This study provides evidence on how universal concepts of self-care and prevention may not aligned with more collectivist societies, emphasizing the limited applicability and motivation of global self-care interventions guidelines for individuals with different cultural backgrounds and values. Therefore, the successful implementation of CC screening programs or any other self-care intervention requires the adoption of culturally appropriate strategies.
The indication for use of the Blue Halo Coil Catheter is to facilitate bladder drainage in adult male patients with urinary retention due to benign prostatic hyperplasia. The device is inserted for temporary use up to 28 days.
The present invention relates to rebescensine A emulsion with high stability and small grain diameters for intravenous injection or intramuscular injection or oral administration and a preparation method thereof. The emulsion of the present invention is characterized in that every 100 ml of the emulsion contains 0.001 to 2g of rubescensine A, 5 to 40g of grease 0.5 to 20g of emulsifying agent, 2.5 to 10g of isoosmotic agent and water for injection. The emulsion has intravenous injection or intramuscular injection or oral administration. All of the patients treated by the emulsion can complete the course of treatment and measurement clinically specified, and clinical therapeutic effects are increased by 40% on the former basis. Patients can hardly accept the stimulation of alcohol preparation static dirppings, so treatment is required to be stopped. The emulsion of the present invention has the advantages of high bioavailability, accurate dose and convenient operation. The intravenous injection emulsion can be distributed rapidly, and has high medicinal effects and targeting performance. Moreover, the grease can also provide certain nutrient energy. The emulsion of the present invention has various ways for feeding medicine, so eligible patients can use the emulsion safely for clinical application. The emulsion has no obvious taste or stimulation, and can be accepted by patients easily.
Systems, methods, and media for measuring health care provider performance and optimizing provision of health care services are provided. A method may include identifying potential chronic conditions a patient has based on a chronic conditions mapping. The method may also comprise determining a cost score. The method may further comprise determining an outcome score. The method may additionally comprise obtaining a final outcome score for each of a plurality of providers based on a variance weighted average of probabilities for groups of metrics pertaining to each provider. The method additionally include generating a final quality index based upon the final outcome score for each provider.
The study population will be consisted of 70 women with POI as the study group and 70 patients with normal healthy women as the control group. A volunteer group of healthy women who will be visited the gynaecology clinic for routine examinations and women who will be admitted for pre-pregnancy tests will be invited randomly to this research as a control group.
Fractures of the proximal humerus constitute approximately 5% of all fractures. Shoulder joint injuries without any external mechanical impact during seizures with the occurrence of spasms occur only sporadically. The occurrence rate is reported in approximately 0.4% of patients. Very rarely they occur in the form of epileptic seizure-induced dorsal fracturedislocation impacting both sides. The case report describes a case of a 48-year-old woman with no treatment for epileptic seizures in her medical history. During the first seizure she sustained a bilateral dorsal fracture-dislocation caused by a muscle spasm, without any other mechanical impact. The fractures were classified as a 3-fragment fracture on the right side and a 4-fragment fracture on the left side. After the patient's admission to the inpatient emergency department, reduction under anaesthesia was attempted. Subsequently, after preparation, open reduction and osteosynthesis using an angularly stable plate were performed as a two-stage surgery. No complications were observed postoperatively Currently, at 3 years after surgeries, the female patient has full mobility of her shoulder joints with no subjective difficulties. Key words: epilepsy, seizure, dorsal fracture-dislocation of the proximal humerus.
Understanding energy expenditure in children with chronic disease is critical due to the impact on energy homeostasis and growth. This systematic review aimed to describe available literature of resting (REE) and total energy expenditure (TEE) in children with chronic disease measured by gold-standard methods of indirect calorimetry (IC) and doubly labeled water (DLW), respectively. A literature search was conducted using OVID Medline, Embase, CINAHL Plus, Cochrane, and Scopus until July 2023. Studies were included if the mean age of the participants was ≤18 y, participants had a chronic disease, and measurement of REE or TEE was conducted using IC or DLW, respectively. Studies investigating energy expenditure in premature infants, patients with acute illness, and intensive care patients were excluded. The primary outcomes were the type of data (REE, TEE) obtained and REE/TEE stratified by disease group. In total, 271 studies across 24 chronic conditions were identified. Over 60% of retrieved studies were published >10 y ago and conducted on relatively small population sizes (n range = 1-398). Most studies obtained REE samples (82%) rather than that of TEE (8%), with very few exploring both samples (10%). There was variability in the difference in energy expenditure in children with chronic disease compared with that of healthy control group across and within disease groups. Eighteen predictive energy equations were generated across the included studies. Quality assessment of the studies identified poor reporting of energy expenditure protocols, which may limit the validity of results. Current literature on energy expenditure in children with chronic disease, although extensive, reveals key future research opportunities. International collaboration and robust measurement of energy expenditure should be conducted to generate meaningful predictive energy equations to provide updated evidence that is reflective of emerging disease-modifying therapies. This study was registered in PROSPERO as CRD42020204690.
The present invention relates to make-up kit compositions which form a double layer structure including a make-up layer and a moisturization/gloss layer when coated on a user′s skin. More specifically, the compositions include first compositions of forming the make-up layer and second compositions for forming the gloss layer separated from each other. The first and second compositions are mixed before being coated on the skin. The make-up kit compositions are separated to the two layer after being coated on the skin. The make-up layer is first attached to the skin, and the moisturizer/gloss layer covers the make-up layer to make the skin glossy. The double-layer formation gives a sensuous and reliable sensation to the user and implements a unique appearance to make the product distinct.
Background: Promotion of cognitive functions of middle aged and older adults and prevention of dementia are important issues in the aging society. In recent years, studies have shown that Tai Chi Chuan (TCC) exercise can improve cognitive functions in healthy middle-aged and older adults, but not studies have investigated the neural mechanisms. Therefore, the purposes of this research project are: (1) to investigate the effects of TCC exercise intervention on improving cognitive functions and motor functions in healthy middle-aged and older adults; (2) to investigate the effects of TCC intervention on improving the integrity of frontostriatal fiber tracts, and areas and intensity of brain activation while performing a switching task in healthy middle-aged and older adults.

Methods: This project used the assessor-blind and randomized control clinical trial design. A total of 60 healthy middle-aged and older adults will be recruited, randomly allocated to two groups: experimental and control groups. Experimental group will receive a 60-minute exercise program, three times per week for 12 weeks. Control group will receive a telephone consultation once every two weeks for 12 weeks. All participants will receive clinical neuropsychological tests, Cambridge Neuropsychological Test Automated Battery tests, motor function tests, diffusion spectrum MR imaging, and functional MRI experiments before intervention, and at the end of intervention to realize the changes of cognitive function, motor function, integrity of neural tracts, and intensity and regions of functional activation while doing switching task of executive function in order to understand the cognitive effects and the neural mechanisms of TCC.
This invention discloses novel antimicrobial materials comprising of nanocrystalline metal, metal oxide, and active oxygen species in a permeable structure. It also discloses the compositions of the inventive material enriched with different active oxygen species. The inventive material showed a strong antimicrobial ability over a wide spectrum of microbies. The average log-reduction value was eight within five minutes. The inventive materials can remain sterile in air over more than two months. The methods used to prepare this inventive material are disclosed.
Neonatal intraventricular hemorrhage (IVH) releases blood products into the lateral ventricles and brain parenchyma. There are currently no medical treatments for IVH and surgery is used to treat a delayed effect of IVH, post-hemorrhagic hydrocephalus. However, surgery is not a cure for intrinsic brain injury from IVH, and is performed in a subacute time frame. Like many neurological diseases and injuries, innate immune activation is implicated in the pathogenesis of IVH. Innate immune activation is a pharmaceutically targetable mechanism to reduce brain injury and post-hemorrhagic hydrocephalus after IVH. Here, we tested the macrolide antibiotic azithromycin, which has immunomodulatory properties, to reduce innate immune activation in an in vitro model of microglial activation using the blood product hemoglobin (Hgb). We then utilized azithromycin in our in vivo model of IVH, using intraventricular blood injection into the lateral ventricle of post-natal day 5 rat pups. In both models, azithromycin modulated innate immune activation by several outcome measures including mitochondrial bioenergetic analysis, cytokine expression and flow cytometric analysis. This suggests that azithromycin, which is safe for neonates, could hold promise for modulating innate immune activation after IVH.
For ALLO-ASC 1xE7 cells/ml,3 patients are to be enrolled. If there is no safety issue, 3 more patients will be enrolled to be treated with ALLO-ASC 3xE7 cells/ml.
A vector associated with a clinical trial is obtained from one or more data sources. The vector comprises one or more fixed elements and one or more optimizable elements. A trial outcome predictor, trained on data related to a plurality of historical clinical trials, is used to determine a probabilistic model of an outcome of the clinical trial based on the vector. An explainability model is used to determine contribution scores for the vector based on the probabilistic model. Each contribution score is indicative of a relative contribution of an associated element of the vector to the outcome of the clinical trial. An explainable prediction of the trial outcome of the clinical trial is generated based on the probabilistic model and one or more of the contribution scores which are associated with the one or more optimizable elements. The explainable prediction is output for review by a user.
No observable teratogenicity was detected in reproductive studies performed in pregnant rats and rabbits. The maternal and developmental no-observable-effect level dosages produced systemic exposures approximately equivalent to or approximately 50% higher in rats and rabbits, respectively, than those seen at the recommended daily human dose (based on AUC). In rats, decreased fetal body weights were observed due to administration of a maternally toxic dose (exposures approximately 50% higher than that seen at the recommended human clinical dose).

There are no adequate and well-controlled studies of VIRAMUNE in pregnant women. The Antiretroviral Pregnancy Registry, which has been surveying pregnancy outcomes since January 1989, has not found an increased risk of birth defects following first trimester exposures to nevirapine. The prevalence of birth defects after any trimester exposure to nevirapine is comparable to the prevalence observed in the general population.

Severe hepatic events, including fatalities, have been reported in pregnant women receiving chronic VIRAMUNE therapy as part of combination treatment of HIV-1 infection. Regardless of pregnancy status, women with CD4+ cell counts >250 cells/mm3 should not initiate VIRAMUNE unless the benefit outweighs the risk. It is unclear if pregnancy augments the risk observed in non-pregnant women [see Boxed Warning].

VIRAMUNE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
1,198,283. Hypotensive medicines. BOEHRINGER INGELHEIM G.m.b.H. 31 July, 1957 [9 Aug., 1966; 14 Feb., 1967], No. 35049/ 67. Heading A5B. [Also in Division C2] The invention comprises (a) pharmaceutical compositions having hypotensive activity comprising, as active ingredient, at least one compound selected from 3-aminosydnonimine deriv:atives of the general formula wherein R 1  and R 2  are each an alkyl, alkenyl, alkynyl, cycloalkyl, aryl or aralkyl group (which may be further substituted by halogen atoms or cyano, trifluoromethyl, alkyl, dialkylamino, dialkylaminoalkyl, hydroxyl, alkoxy, acyloxy, acyl or hydroxyalkyl groups or an oxydimethylene or methylenedioxy group) or a heterocyclic ring system linked via an alkylene chain to the nitrogen atom of the 3-amino group, or R 1  and R 2 , together with the adjacent nitrogen atom, represent a heterocyclic ring system which may contain one or more further heteroatoms and may be substituted by at least one halogen atom, hydroxyl group or C 1-2  alkyl, alkoxy, acyl, acyloxy, hydroxyalkyl, alkoxyalkyl or haloalkyl radical or an aryl or aralkyl group; R 3  is a hydrogen atom or an alkyl or aralkyl group; and R 4  is a hydrogen atom or the group of formula R 5 CO (where R 5  is an alkyl, cycloalkyl or alkoxy group, or an aryl, aralkyl or heterocyclic radical, each of which last-mentioned radicals may be substituted by a methyl or nitro group or a halogen atom) or non-toxic acid addition salt thereof [with the exception of 3-amino-sydnonimine derivatives of the general formula wherein R 3  is a hydrogen atom or a C 1-5  alkyl group and R 1  and R 2  are each a C 1-5  alkyl or C 2-5  alkenyl group, or R 1  and R 2 , together with the nitrogen atom to which they are attached, represent a morpholino or pipecolino group, a group of the formula wherein n is 4, 5 or 6, a group of the formula wherein R' is a C 1-5  alkyl group, or a group of the formula and pharmaceutically acceptable salts thereof], and 3-diallylamino-sydnonimine, 3-di-ethylaminosydnonimine, 3-diallylamino-4-methyl-sydnonimine and 3-diallylamino-4-ethyl-sydonimine and non-toxic acid addition salts thereof, together with a pharmaceutical carrier or excipient in a form suitable for enteral or parenteral administration; and (6) pharmaceutical compositions in doseage unit form adapted for oral administration having hypotensive activity comprising, as active ingredient, a 3-amino-syndnonimine derivative of the first general formula above, being also within the scope of the second general formula above or a non-toxic acid addition salt thereof, together with a pharmaceutical carrier or excipient, and each said dosage unit containing from 10 to 100 mg. of active ingredient. The compositions may also contain a further therapeutic compound, e.g. a compound having saluretic activity.
A multi-functional portable electro-medical device (10) provides interferential current stimulation to promote bone growth. Two electrical signals are applied to a target area, each electrical signal being formed by a set of two electrode pads. A beat frequency is created at the location the signals intersect with each other. The beat frequency is the difference between the frequencies of the two signals and has an amplitude that is additive and greater than either signal alone. The depth of the interferential signal is increased by increasing the carrier frequency of the signals. The direction of the interferential signal shifts toward the signal having the lower amplitude. The electrical stimulation is used in combination with biologics to further increase bone growth. The target area is large enough to include multiple vertebral segments.
Patients receive telaglenastat hydrochloride PO BID and osimertinib PO QD (starting cycle 1 day 16 of phase I). Patients undergo blood sample collection and may undergo x-ray imaging, CT scan, MRI, or PET scan throughout the study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Pelvic organ prolapse is a common debilitating condition worldwide. Despite surgical treatment, its recurrence can reach up to 30%. It has multiple risk factors, some of which are particular for a low-resource settings. The identification these factors would help to devise risk models allowing the development of prevention policies. The objective of this study was to explore risk factors for pelvic organ prolapse in a population in eastern Democratic Republic of Congo (DRC).
METHODS: This was an unmatched case-control study conducted between January 2021 and January 2022. The sample size was estimated to be a total of 434 women (217 with prolapse as cases and 217 without prolapse as controls). Data comparisons were made using the Chi-Square and Student T tests. Binary and multivariate logistic regressions were used to determine associated factors. A p < 0.05 was considered significant.
RESULTS: Variables identified as definitive predictors of pelvic organ prolapse included low BMI (aOR 2.991; CI 1.419-6.307; p = 0.004), home birth (aOR 6.102; CI 3.526-10.561; p < 0.001), family history of POP (aOR 2.085; CI 1.107-3.924; p = 0.023), history of birth without an episiotomy (aOR 3.504; CI 2.031-6.048; p = 0), height ≤ 150 cm (aOR 5.328; CI 2.942-9.648; p < 0.001) and history of giving birth to a macrosomic baby (aOR 1.929; IC 1.121-3.321; p = 0.018).
CONCLUSIONS: This study identified that Body Mass Index and birth-related factors are definitive predictors of pelvic organ prolapse in a low-resource setting. These factors are potentially modifiable and should be targeted in any future pelvic organ prolapse prevention policy. Additionally, there seems to be a genetic predisposition for prolapse, which warrants further assessment in specifically designed large scale studies.
Routine oesophageal pH investigation involves the trans-nasal placement of a microelectrode into the distal oesophagus as per hospital protocol. Examining the oropharynx and confirming visualisation of the red LED at the catheter tip in the correct position just below the soft palate will confirm its position in the oropharynx. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.